| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Hans van Houte is Chief Financial Officer at NRIX. Hans van Houte's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
Historically, Hans van Houte's trades have earned a middling insider score of 56/100 across 32 rated trades. Over a 12-month horizon, 52.0% of those trades were profitable, with an average 12-month return of -19.2%.
The NRIX filings lean toward selling, a net 207,123 shares.
Hans van Houte has 44 Form 4 filings on record from February 2021 to October 2026, all as Chief Financial Officer at Nurix Therapeutics (NRIX), 2021–2026.
The 111 reported transactions were 53 option exercises, 46 open-market sales and 12 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 36 sales worth about $4.7M.
The largest open-market sale was 35,419 shares of NRIX at an average $39.90 on February 24, 2021, about $1.4M.
14 of the 29 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 15 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,834 | $26.28 | $74,474.97 | -5.6% | - | - | |
| Aug 4, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 4,761 | $24.36 | $115,989.47 | -10.6% | +9.8% | - | |
| Jul 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,845 | $23.38 | $66,524.07 | -6.0% | +15.6% | - | |
| May 5, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 14,055 | $16.60 | $233,318.97 | -27.2% | +39.9% | - | |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 2,388 | $16.65 | $39,748.98 | -4.4% | +41.3% | - | |
| Jan 30, 2026 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,661 | $16.60 | $60,766.50 | -7.5% | +1.1% | - | |
| Nov 3, 2025 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 6,284 | $12.56 | $78,931.44 | -14.3% | +35.4% | +114.9% | |
| Oct 30, 2025 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 3,130 | $12.80 | $40,053.67 | -6.7% | +39.8% | +112.2% | |
| Aug 1, 2025 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sell10b5-1 | 5,402 | $11.03 | $59,597.57 | -13.2% | +15.8% | +110.2% | |
| Jul 30, 2025 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 4,304 | $12.01 | $51,695.34 | -9.5% | +0.2% | - |